Advertisement

Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society

  • Robert Melamede

Abstract

Living systems are far from equilibrium open systems that exhibit many scales of emergent behavior. They may be abstractly viewed as a complex weave of dissipative structures that maintain organization by passing electrons from reduced hydrocarbons to oxygen. Free radicals are unavoidable byproducts of biological electron flow. Due to their highly reactive chemical properties, free radicals modify all classes of biological molecules (carbohydrates, lipids, nucleic acids, and proteins). As a result, free radicals are destructive. The generally disruptive nature of free radicals makes them the “friction of life.” As such, they are believed to be the etiological agents behind age related illnesses such as cardiovascular, immunological, and neurological diseases, cancer, and ageing itself. Free radicals also play a critical constructive role in living systems. From a thermodynamic perspective, life can only exist if a living system takes in sufficient negative entropy from its environment to overcome the obligatory increase in entropy that would result if the system could not appropriately exchange mass, energy and information with its environment. Free radicals are generated in response to perturbations in the relationship between a living system and its environment. However, evolution has selected for biological response systems to free radicals so that the cellular biochemistry can adapt to environmental perturbations by modifying cellular gene expression and biochemistry. Endocannabinoids are marijuana-like compounds that have their origins hundreds of millions of years in the evolutionary past. They serve as fundamental modulators of energy homeostasis in all vertebrates. Their widespread biological activities may often be attributed to their ability to minimize the negative consequences of free radicals.

Keywords

Irritable Bowel Syndrome Dissipative Structure Emergent Behavior Medicinal Cannabis Molecular Face 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    Amodio, DM, JT Jost, SL Master, and CM Yee. 2007. Neurocognitive correlates of liberalism and conservatism. Nature Neuroscience 10, no. 10: 1246–1247.CrossRefGoogle Scholar
  2. 2.
    Barnwell, SS, M Earleywine, and R Wilcox. 2006. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy 1, no. 1:2.CrossRefGoogle Scholar
  3. 3.
    Bilkei-Gorzo, A, I Racz, O Valverde, M Otto, K Michel, M Sastre, and A Zimmer. 2005. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proceedings of the National Academy of Sciences of the United States of America 102, no. 43: 15670–15675.ADSCrossRefGoogle Scholar
  4. 4.
    Brady, CM, R DasGupta, C Dalton, OJ Wiseman, KJ Berkley, and CJ Fowler. 2004. An open-label pilot study of cannabis—based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 10, no. 4: 425–433.CrossRefGoogle Scholar
  5. 5.
    Burns, TL, and JR Ineck. 2006. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 40, no. 2: 251–260.CrossRefGoogle Scholar
  6. 6.
    2003. Cannabis-based medicines—GW pharmaceuticals: high CBD, high THC, medicinal cannabis—GW pharmaceuticals, THC:CBD. Drugs R D 4, no. 5: 306–309.Google Scholar
  7. 7.
    Carrier, EJ, S Patel, and CJ Hillard. 2005. Endocannabinoids in neuroimmundogy and stress. CurrDrug Targets CNS Neurol Disord 4, no. 6: 657–665.CrossRefGoogle Scholar
  8. 8.
    Casanova, ML, C Blazquez, J Martinez-Palacio, C Villanueva, M J Fernandez-Acenero, JW Huffman, JL Jorcano, and M Guzman. 2003. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111, no. 1: 43–50.Google Scholar
  9. 9.
    Chevaleyre, V, KA Takahashi, and PE Castillo. 2006. Endocannabinoid-mediated synaptic plasticity in the CNS. Annual Review of Neuro science 29, 37–76.CrossRefGoogle Scholar
  10. 10.
    Cota, D, G Marsicano, M Tschop, Y Grubler, C Flachskamm, M Schubert, D Auer, A Yassouridis, C Thone-Reineke, S Ortmann, F Tomassoni, C Cervino, E Nisoli, AC Linthorst, R Pasquali, B Lutz, GK Stalla, and U Pagotto. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation 112, no. 3: 423–431.Google Scholar
  11. 11.
    Cota, D, MH Tschop, TL Horvath, and AS Levine. 2005. Cannabinoids, opioids and eating behavior: The molecular face of hedonism? Brain Res Brain Res Rev Google Scholar
  12. 12.
    Denson, TF, and M Earleywine. 2006. Decreased depression in marijuana users. Addict Behavll, no. 4: 738–742.CrossRefGoogle Scholar
  13. 13.
    Devane, WA, L Hanus, A Breuer, RG Pertwee, LA Stevenson, G Griffm, D Gibson, A Mandelbaum, A Etinger, and R Mechoulam. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, no. 5090: 1946–1949.ADSCrossRefGoogle Scholar
  14. 14.
    Fride, E. 2005. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord 4, no. 6: 633–642.Google Scholar
  15. 15.
    Guzman, M. 2003. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3, no. 10: 745–755.Google Scholar
  16. 16.
    Guzman, M. 2005. Effects on cell viability. Handb Exp Pharmacol no. 168: 627–642.Google Scholar
  17. 17.
    Herkenham, M, AB Lynn, MD Little, MR Johnson, LS Melvin, BR de Costa, and KC Rice. 1990. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 87, no. 5: 1932–1936.ADSCrossRefGoogle Scholar
  18. 18.
    Hill, MN, LM Froese, AC Morrish, JC Sun, and SB Floresco. 2006. Alterations in behavioral flexibility by cannabinoid CB(1) receptor agonists and antagonists. Psychopharmacology (Berl) Google Scholar
  19. 19.
    Hill, MN, and BB Gorzalka. 2005. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behavioural Pharmacology 16, no. 5-6: 333–352.CrossRefGoogle Scholar
  20. 20.
    Hollister, LE. 1971. Actions of various marihuana derivatives in man. Pharmacol Rev 23, no. 4: 349–357.Google Scholar
  21. 21.
    Izzo, AA, and AA Coutts. 2005. Cannabinoids and the digestive Xxact. Handb Exp Pharmacol no. 168: 573–598.CrossRefGoogle Scholar
  22. 22.
    Jiang, W, Y Zhang, L Xiao, J Van Cleemput, SP Ji, G Bai, and X Zhang. 2005. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. Journal of Clinical Investigation 115, no. 11:3104–3116.CrossRefGoogle Scholar
  23. 23.
    Kondepudi, Dilip, and I. Prigogine. 1998. Modern Thermodynamics: From Heat Engines to Dissipative Structures. John Wiley & Sons.Google Scholar
  24. 24.
    Li, X, NE Kaminski, and LJ Fischer. 2001. Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol 1, no. 4: 699–712.CrossRefGoogle Scholar
  25. 25.
    Maccarrone, M, and T Wenger. 2005. Effects of cannabinoids on hypothalamic and reproductive function. Handb Exp Pharmacol no. 168: 555–571.CrossRefGoogle Scholar
  26. 26.
    Massa, F, and K Monory. 2006. Endocannabinoids and the gastrointestinal tract. Journal of Endocrinological Investigation 29, no. 3 Suppl: 47–57.Google Scholar
  27. 27.
    McPartland, JM, J Agraval, D Gleeson, K Heasman, and M Glass. 2006. Cannabinoid receptors in invertebrates. J Evol Biol 19, no. 2: 366–373.CrossRefGoogle Scholar
  28. 28.
    Melamede, R. 2005. Harm reduction—the cannabis paradox. Harm Reduct J 2, 17.CrossRefGoogle Scholar
  29. 29.
    Melamede, RJ. 2006a. Cannabinoids and the Physics of Life. Fourth National Conference on Clinical Cannabinoids Google Scholar
  30. 30.
    Melamede, RJ. 2006b. Dissipative Structures and the Origins of Life. 601Google Scholar
  31. 31.
    Milton, NG. 2002. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neuroscience Letters 332, no. 2: 127–130.Google Scholar
  32. 32.
    Narang, S, D Gibson, AD Wasan, EL Ross, E Michna, SS Nedeljkovic, and RN Jamison. 2008. Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. J Pain 9, no. 3: 254–264.CrossRefGoogle Scholar
  33. 33.
    Nicolis, Grégoire, and Ilya Prigogine. 1989. Exploring Complexity: An Introduction. W.H. Freeman & Company.Google Scholar
  34. 34.
    Ofek, O, M Karsak, N Leclerc, M Fogel, B Frenkel, K Wright, J Tarn, M Attar-Namdar, V Kram, E Shohami, R Mechoulam, A Zimmer, and I Bab. 2006. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proceedings of the National Academy of Sciences of the United States of America 103, no. 3: 696–701.ADSCrossRefGoogle Scholar
  35. 35.
    Piomelli, D, G Tarzia, A Duranti, A Tontini, M Mor, TR Compton, O Dasse, EP Monaghan, JA Parrott, and D Putman. 2006. Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597). CNS Drug Rev 12, no. 1: 21–38.CrossRefGoogle Scholar
  36. 36.
    Ramirez, BG, C Blazquez, T Gomez del Pulgar, M Guzman, and ML de Ceballos. 2005. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of’ Neuroscience 25, no. 8: 1904–1913.CrossRefGoogle Scholar
  37. 37.
    Russo, EB. 2004. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 25, no. 1-2: 31–39.Google Scholar
  38. 38.
    Russo, EB, GW Guy, and PJ Robson. 2007. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. Chem Biodivers 4, no. 8: 1729–1743.CrossRefGoogle Scholar
  39. 39.
    Shohami, E, and R Mechoulam. 2006. Multiple sclerosis may disrupt endocannabinoid brain protection mechanism. Proceedings of the National Academy of Sciences of the United States of America 103, no. 16: 6087–6088.ADSCrossRefGoogle Scholar
  40. 40.
    Steffens, S, NR Veillard, C Arnaud, G Pelli, F Burger, C Staub, A Zimmer, JL Frossard, and F Mach. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, no. 7034: 782–786.ADSCrossRefGoogle Scholar
  41. 41.
    Tomida, I, A Azuara-Blanco, H House, M Flint, RG Pertwee, and PJ Robson. 2006. Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study. Journal of Glaucoma 15, no. 5: 349–353.CrossRefGoogle Scholar
  42. 42.
    Varvel, SA, and AH Lichtman. 2002. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301, no. 3: 915–924.CrossRefGoogle Scholar
  43. 43.
    Wang, H, SK Dey, and M Maccarrone. 2006. Jekyll and Hyde: Two Faces of Cannabinoid Signaling in Male and Female Fertility. Endocrine Reviews Google Scholar
  44. 44.
    Zimmer, A, AM Zimmer, AG Hohmann, M Herkenham, and TI Bonner. 1999. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 96, no. 10: 5780–5785.ADSCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Robert Melamede
    • 1
  1. 1.University of ColoradoColorado Springs

Personalised recommendations